Biodel (NASDAQ:BIOD) Current price $2.70
On Thursday, the firm reported positive top-line results from a Phase 1 clinical trial of two ultra-rapid-acting insulin analog-based formulations, BIOD-238 and BIOD-250, conducted to study the pharmacokinetic and injection site toleration profiles relative to Humalog, which is a quickly-acting insulin analog. BIOD-238 and BIOD-250 are combinations of Biodel’s proprietary excipients with the marketed formulation of Humalog.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.